59.05
-1.15 (-1.91%)
| Previous Close | 60.20 |
| Open | 57.50 |
| Volume | 8,076,820 |
| Avg. Volume (3M) | 7,665,505 |
| Market Cap | 20,859,410,432 |
| Price / Sales | 21.09 |
| Price / Book | 4.96 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 |
| Profit Margin | -147.36% |
| Operating Margin (TTM) | -26.77% |
| Diluted EPS (TTM) | -3.55 |
| Quarterly Revenue Growth (YOY) | 246.20% |
| Total Debt/Equity (MRQ) | 14.13% |
| Current Ratio (MRQ) | 2.54 |
| Operating Cash Flow (TTM) | -679.51 M |
| Levered Free Cash Flow (TTM) | -689.60 M |
| Return on Assets (TTM) | -9.09% |
| Return on Equity (TTM) | -23.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | EVEREST MED | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| EVEREST MED | 21 B | - | - | 4.96 |
| BEIGENE | 316 B | - | - | 9.69 |
| HENLIUS | 43 B | - | 47.62 | 11.59 |
| INNOCARE | 39 B | - | - | 4.18 |
| ASCENTAGE-B | 29 B | - | - | 39.59 |
| INNOVENT BIO | 152 B | - | - | 10.52 |
|
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.57% |
| % Held by Institutions | 33.61% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |